

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

**ACQUISITION OF THE REMAINING 49%
EQUITY INTERESTS IN FULILONG**

The Board would like to announce that as at the date of this announcement, the application of Fulilong for the land use right certificate in respect of one piece of collective construction land in Dongguan, the People's Republic of China occupied by it for its production workshops was still being processed and the relevant land use right certificate has not been granted to Fulilong. The Company shall issue an announcement as soon as practicable after obtaining of the land use right certificate by Fulilong.

Reference is made to the announcement (the "Announcement") and the circular (the "Circular") in relation to the acquisition of the remaining 49% equity interests in Fulilong dated 30 June and 28 August 2006 respectively. Terms used in this announcement shall have the same meaning as they are defined in the Circular unless they are defined otherwise in this announcement.

As mentioned in the Announcement and the Circular, Fulilong had submitted an application for the land use right certificate in respect of one piece of collective construction land in Dongguan, the People's Republic of China occupied by it for its production workshops which application was expected to have been processed completely by the end of December 2006 and an announcement would be made as soon as practicable when there was any new development in respect of the application. The Board of Directors (the "Board") of Tianjin TEDA Biomedical Engineering Company Limited (the "Company") would like to announce that as at the date of this announcement, the application was still being processed and the relevant land use right certificate has not been granted to Fulilong. The Company shall issue an announcement as soon as practicable after obtaining of the land use right certificate by Fulilong.

By order of the Board
Wang Shuxin
Chairman

Tianjin, the PRC
5 January 2007

As at the date of this announcement, the Board comprises three executive directors, being Mr. Wang Shuxin, Mr. Xie Kehua and Mr. Zhang Songhong; three non-executive directors, being Mr. Feng Enqing, Mr. Liu Zhenyu and Mr. Xie Guangbei; and three independent non-executive directors, being Professor Xian Guoming, Mr. Wu Chen and Mr. Guan Tong.

This announcement, for which the directors of Tianjin TEDA Biomedical Engineering Company Limited (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Tianjin TEDA Biomedical Engineering Company Limited. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for at least 7 days from the day of its posting.